Tian Zhang, MD, Duke Cancer Center, Durham, NC, discusses the PAPMET study (NCT02761057), which is investigating MET inhibitors in patients with papillary renal cell carcinoma (pRCC). Patients treated with the MET inhibitor cabozantinib demonstrated improved median progression-free survival when compared to standard of care sunitinib. As a result, cabozantinib gained recognition as a standard of care option for patients with pRCC. This interview took place during the 2021 Genitourinary Cancers Symposium.